Kanuma(sebelipase alfa)
Kanuma (sebelipase alfa) is an enzyme pharmaceutical. Sebelipase alfa was first approved as Kanuma on 2015-08-28. It has been approved in Europe to treat inborn errors lipid metabolism.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Kanuma
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Sebelipase alfa
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Kanuma | sebelipase alfa | Alexion Pharmaceuticals | N-125561 RX | 2015-12-08 | 1 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| kanuma | Biologic Licensing Application | 2025-07-21 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
sebelipase alfa, Kanuma, Alexion Pharmaceuticals, Inc. | |||
| 2122-12-08 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J2840 | Injection, sebelipase alfa, 1 mg |
Clinical
Clinical Trials
9 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Wolman disease | D015223 | Orphanet_75233 | E75.5 | 1 | 5 | 2 | — | 2 | 8 |
| Failure to thrive | D005183 | — | — | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fabry disease | D000795 | Orphanet_324 | E75.21 | 1 | 2 | — | — | — | 2 |
| Cholesterol ester storage disease | D015217 | — | — | 1 | 2 | — | — | — | 2 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Sebelipase alfa |
| INN | sebelipase alfa |
| Description | Sebelipase alfa, sold under the brand name Kanuma, is a recombinant form of the enzyme lysosomal acid lipase (LAL) that is used as a medication for the treatment of lysosomal acid lipase deficiency (LAL-D). It is administered via intraveneous infusion. It was approved for medical use in the European Union and in the United States in 2015.
|
| Classification | Enzyme |
| Drug class | enzymes |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 1276027-63-4 |
| RxCUI | 1726975 |
| ChEMBL ID | CHEMBL3039537 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB11563 |
| UNII ID | K4YTU42T8G (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Kanuma – Alexion Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Kanuma – AstraZeneca
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 501 documents
View more details
Safety
Black-box Warning
Black-box warning for: Kanuma
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
626 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use